CTRI Number |
CTRI/2024/02/062193 [Registered on: 01/02/2024] Trial Registered Prospectively |
Last Modified On: |
30/01/2024 |
Post Graduate Thesis |
Yes |
Type of Trial |
Observational |
Type of Study
|
Cross Sectional Study |
Study Design |
Other |
Public Title of Study
|
To Compare the Crystallization Patterns in Blood Samples of Oral Submucous Fibrosis, Oral Cancer and Healthy Individuals |
Scientific Title of Study
|
Comparative Evaluation Of Crystallization Patterns In Oral Submucous Fibrosis, Oral Squamous Cell Carcinoma and Healthy Individuals- A Prospective Serological Study |
Trial Acronym |
nil |
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
MRUDULA KATARNI |
Designation |
Post Graduate Student |
Affiliation |
MGM DENTAL COLLEGE AND HOSPITAL NAVI MUMBAI |
Address |
Room no. 505, 5th floor, MGM DENTAL COLLEGE AND HOSPITAL , Junction between NH4 and Sion Panvel Hwy, Kamothe, NAVI MUMBAI Room no. 505, 5th floor, MGM DENTAL COLLEGE AND HOSPITAL , Junction between NH4 and Sion Panvel Hwy, Kamothe, NAVI MUMBAI Raigarh MAHARASHTRA 410209 India |
Phone |
09970634440 |
Fax |
|
Email |
drmrudulakatarni@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
DR KAMLESH DEKATE |
Designation |
ASSOCIATE PROFESSOR |
Affiliation |
MGM DENTAL COLLEGE AND HOSPITAL NAVI MUMBAI |
Address |
Room no. 505, 5th floor, MGM DENTAL COLLEGE AND HOSPITAL , Junction between NH4 and Sion Panvel Hwy, Kamothe, NAVI MUMBAI Room no. 505, 5th floor, MGM DENTAL COLLEGE AND HOSPITAL , Junction between NH4 and Sion Panvel Hwy, Kamothe, NAVI MUMBAI Raigarh MAHARASHTRA 410209 India |
Phone |
9223290372 |
Fax |
|
Email |
dr.kamleshdekate@gmail.com |
|
Details of Contact Person Public Query
|
Name |
DR KAMLESH DEKATE |
Designation |
ASSOCIATE PROFESSOR |
Affiliation |
MGM DENTAL COLLEGE AND HOSPITAL NAVI MUMBAI |
Address |
Room no. 505, 5th floor, MGM DENTAL COLLEGE AND HOSPITAL , Junction between NH4 and Sion Panvel Hwy, Kamothe, NAVI MUMBAI Room no. 505, 5th floor, MGM DENTAL COLLEGE AND HOSPITAL , Junction between NH4 and Sion Panvel Hwy, Kamothe, NAVI MUMBAI Raigarh MAHARASHTRA 410209 India |
Phone |
9223290372 |
Fax |
|
Email |
dr.kamleshdekate@gmail.com |
|
Source of Monetary or Material Support
|
MGM Dental College and Hospital, Junction of NH4 and Sion-Panvel HWy, Sector 18, Navi Mumbai, Maharashtra 410209 |
|
Primary Sponsor
|
Name |
MGM Dental college and hospital |
Address |
Junction of NH4 and Sion-Panvel Hwy, Sector 18, Navi Mumbai, Maharashtra 410209 |
Type of Sponsor |
Research institution and hospital |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Mrudula Katarni |
MGM Dental College and Hospital, Navi Mumbai |
room no 505, 5th floor , MGM Dental college and Hospital, junction of NH4 and Sion-Panvel Hwy, Sector 18, Navi Mumbai Raigarh MAHARASHTRA |
9970634440
drmrudulakatarni@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
INSTITUTIONAL ETHICS COMMITTEE MAHATMA GANDHI MISSIONS DENTAL COLLEGE & HOSPITAL |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: C00-C14||Malignant neoplasms of lip, oral cavity and pharynx, (2) ICD-10 Condition: K135||Oral submucous fibrosis, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Intervention |
nil |
NIL |
|
Inclusion Criteria
|
Age From |
15.00 Year(s) |
Age To |
70.00 Year(s) |
Gender |
Both |
Details |
Group I- Clinically diagnosed cases of Oral submucous fibrosis
Group II- Clinicopathologically diagnosed cases of Oral Squamous Cell Carcinoma
Group III- Healthy individuals advised for blood investigations for routine dental surgical procedures without any known medical history
|
|
ExclusionCriteria |
Details |
Group I-
1.Patients undergoing treatment for OSMF
2.Patient with history of scleroderma, amyloidosis, generalized fibromatosis.
3. Patients with systemic conditions like heart diseases, diabetes mellitus, thyrotoxicosis, liver diseases, pregnancy, oestrogen therapy, etc.
4.Patients those who are not willing to participate.
Group II
1. Recurrent cases of oral squamous cell carcinoma
2. Patients undergoing /undergone treatment of OSCC.
3. Patients with systemic conditions like heart diseases, diabetes mellitus, thyrotoxicosis, liver diseases, pregnancy, oestrogen therapy, etc
4. Patients diagnosed other than OSCC after histopathological examination.
5. Patients those who are not willing to participate.
Group III
1. Patients those who are not willing to participate |
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Not Applicable |
Primary Outcome
|
Outcome |
TimePoints |
To Evaluate and Compare the Crystallization Patterns in Oral Submucous Fibrosis, Oral Squamous Cell Carcinoma and Healthy Individuals |
Blood samples will be collected at the time of patient presentation from Oral Submucous Fibrosis Oral Squamous Cell Carcinoma patients and healthy individuals. The crystallization patterns will be observed 24 hours after the sample collection and crystallization patterns of oral submucous fibrosis and oral squamous cell carcinoma will be compared with the crystallization patterns of healthy individuals |
|
Secondary Outcome
|
Outcome |
TimePoints |
To compare the crystallization patterns in different clinical stages in Oral Submucous Fibrosis Cases. |
After taking a patients informed consent detailed case history will be taken for study group & blood samples will be collected |
|
Target Sample Size
|
Total Sample Size="114" Sample Size from India="114"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
14/02/2024 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
Recruitment Status of Trial (India) |
Not Yet Recruiting |
Publication Details
|
N/A |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
|
Oral submucous fibrosis (OSMF) is a chronic impairing
disease of oral and oropharyngeal mucosa which was historically described by
Pindborg and Sirsat in 1966 as “an insidious chronic disease affecting any
part of the oral cavity and sometimes pharynx. Although occasionally preceded
by and/or associated with vesicle formation, it is always associated with
juxta-epithelial inflammatory reaction followed by fibroblastic changes in
the lamina propria, with epithelial atrophy leading to stiffness of the oral
mucosa causing trismus and difficulty in eating.†The oral manifestations include symptoms like burning
sensation, blanching and leathery
texture of the oral mucosa, submucosal fibrous
bands, gradual reduction of mouth opening,
reduced movement and depapillation of the tongue, and shrunken uvula
It is mostly related with the areca nut
chewing habit, which is consumed in different types of formulations by
10–20% of the World’s population. According
to world Health Organization OSMF affected more than 5 million people all
around the world. In Indian population the prevalence
rate has changed from 0.03% to 6.4% in last four decades . Oral submucous fibrosis is one of the most
common oral potentially malignant disorders, with nearly 4% rate of
transformation into oral squamous cell carcinoma. To judge the
severity of the disease, various
researchers proposed several classifications based on clinical and histological
features, based on various aspects of OSMF. Squamous
cell carcinoma is defined as “a malignant epithelial neoplasm exhibiting
squamous differentiation as characterized by the formation of keratin and/or
the presence of intercellular bridgesâ€. Studies suggest
that in India, that many oral cancers are diagnosed in advanced stages due to
insufficient approach toward disease leading to 60 to 80% of mortality rate. There is difference in
clinical presentations of Oral submucous fibrosis and Oral squamous cell
carcinoma and most of the oral cancers are asymptomatic in preliminary
stages. There is greater probability of misdiagnosis when OSMF undergoing
malignant transformation . Also lack of awareness amongst
general practitioners causes failure to refer the patients for
investigations, leading to diagnostic delay. Hence, early diagnosis and
treatment of carcinoma is the key in improving the survival rates. In presence of various confounding factors
like overlapping of clinical features, difficulty in assessment of OSMF
patients of advanced stages and post operative healing complications, makes
it challenging for the screening and staging of OSMF patients. As this
disease carries high risk of malignant transformation, the early screening
and clinical staging of OSMF is necessary for the risk assessment of the carcinomatous
changes. Therefore, the efficacy of minimally invasive screening techniques
should be tested. Some of these includes cytological, biochemical,
histopathological, and optical diagnostic methods. In
addition to these methods, Biocrystallization test is one such physical test that
utilizes the phenomenon of morphogenetic forces. In this salt of cupric
chloride is used to test quality of the substance without interacting with
the test substance itself, resulting in slow crystallization. These slow growing
crystals takes the form of different patterns, that can be studied for
determining the quality of the test substance. Pfeiffer
and Steiner introduced this sensitive crystallization technique in 1938 which
is blood-based qualitative method. They conducted an experiment by adding
cupric chloride (CuCl2) solution to diluted hemolyzed human blood of cancer patients . This colloidal solutions mixture gave rise to organic and inorganic
salts that created various crystallization patterns due to different rates
and amplitudes of molecular movements during evaporation .
Thus, it was stated that hemolyzed blood containing colloidal proteins
contributed to crystallization patterns. In other way, the
concept of biocrystallization was based on the oxidative stress which is induced
by the internal metabolic conditions. These crystallization forms appear to
be “Transverse bar Formations†, “Muddle Formations†and “Hollow Glans Formationsâ€
patterns as peculiar findings in premalignancy and malignancy. To observe the changes
in blood samples during routine hematological practice at early stage of
carcinogenesis or even at the premalignant phase, such kind of diagnostic approach
is need of hour in research. Pfeiffer crystallization method is simple, economical,
dependable, less time-consuming and a minimally invasive method for early
detection of cancer. This makes it more suitable for mass screening for
premalignant and malignant lesions. In addition, this technique
will help in early detection of cancer transforming lesion, that would
ultimately help in enhancing the prognosis and increase the patient survival
rate for individuals with an elevated risk or genetic predisposition. This shall
potentially reduce the burden of cancer on patients and their families.
Moreover, the healthcare systems can reach people from both rural and urban
areas for early screening programs, that will in turn benefit the society to
build up a healthy population, especially in developing countries. Hence, it
can be used in correlation with the clinical and histopathological grading
for the precancerous lesions where biopsy is infrequently recommended. Therefore, the current
study aims to compare the patterns of crystallization and to further confirm
the efficacy of crystallization test as a screening modality in Oral
Submucous Fibrosis and Oral Squamous Cell Carcinoma.
|
|